Total Payments
$79,371
2024 Payments
$15,509
Companies
45
Transactions
417
Medicare Patients
3,829
Medicare Billing
$480,236
Payment Breakdown by Category
Research$41,440 (52.2%)
Other$16,300 (20.5%)
Consulting$9,875 (12.4%)
Food & Beverage$8,720 (11.0%)
Travel$2,748 (3.5%)
Education$287.66 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $41,440 | 20 | 52.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,300 | 6 | 20.5% |
| Consulting Fee | $9,875 | 4 | 12.4% |
| Food and Beverage | $8,720 | 361 | 11.0% |
| Travel and Lodging | $2,748 | 5 | 3.5% |
| Education | $287.66 | 21 | 0.4% |
Payments by Type
Research
$41,440
20 transactions
General
$37,931
397 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. | $41,492 | 24 | $0 (2024) |
| Krystal Biotech Inc | $26,052 | 19 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,313 | 56 | $0 (2024) |
| PFIZER INC. | $849.95 | 50 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $745.42 | 11 | $0 (2024) |
| ABBVIE INC. | $520.05 | 24 | $0 (2024) |
| GENZYME CORPORATION | $490.50 | 14 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $416.23 | 15 | $0 (2024) |
| Galderma Laboratories, L.P. | $411.99 | 24 | $0 (2023) |
| MAYNE PHARMA INC. | $357.62 | 14 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,509 | 32 | Arcutis Biotherapeutics, Inc. ($11,043) |
| 2023 | $56,930 | 77 | Arcutis Biotherapeutics, Inc. ($30,449) |
| 2022 | $1,107 | 42 | GENZYME CORPORATION ($307.20) |
| 2021 | $868.61 | 37 | PFIZER INC. ($244.57) |
| 2020 | $398.93 | 17 | Regeneron Healthcare Solutions, Inc. ($144.54) |
| 2019 | $1,018 | 47 | Novartis Pharmaceuticals Corporation ($227.93) |
| 2018 | $1,681 | 77 | Novartis Pharmaceuticals Corporation ($474.02) |
| 2017 | $1,858 | 88 | Novartis Pharmaceuticals Corporation ($413.32) |
All Payment Transactions
417 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | — | Cash or cash equivalent | $245.00 | Research |
| Study: A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis • Category: Dermatology | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | — | Cash or cash equivalent | $5,125.34 | Research |
| Study: A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis • Category: Dermatology | ||||||
| 12/02/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis • Category: Dermatology | ||||||
| 11/12/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $16.07 | General |
| Category: Dermatology | ||||||
| 11/09/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $18.43 | General |
| Category: Dermatology | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $47.33 | General |
| Category: Dermatology | ||||||
| 10/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $47.06 | General |
| 10/13/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: Dermatology | ||||||
| 10/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $41.57 | General |
| Category: Immunology | ||||||
| 10/02/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $19.89 | General |
| Category: Immunology | ||||||
| 09/24/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Inflammation | ||||||
| 09/12/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | — | Cash or cash equivalent | $875.68 | Research |
| Study: A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302 • Category: Dermatology | ||||||
| 09/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: IMMUNOLOGY | ||||||
| 08/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $29.56 | General |
| Category: Immunology | ||||||
| 08/14/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $5.22 | General |
| Category: Dermatology | ||||||
| 07/19/2024 | Krystal Biotech Inc | VYJUVEK (Drug) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: DERMATOLOGY | ||||||
| 06/20/2024 | Krystal Biotech Inc | VYJUVEK (Drug) | Food and Beverage | In-kind items and services | $12.20 | General |
| Category: DERMATOLOGY | ||||||
| 06/12/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $3.69 | General |
| Category: DERMATOLOGY | ||||||
| 06/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: IMMUNOLOGY | ||||||
| 05/22/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: DERMATOLOGY | ||||||
| 05/01/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Dermatology | ||||||
| 05/01/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $11.53 | General |
| Category: Dermatology | ||||||
| 03/07/2024 | Krystal Biotech Inc | VYJUVEK (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: DERMATOLOGY | ||||||
| 03/06/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | $22,725 | 10 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | $14,642 | 5 |
| A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis who have Completed Preceding Studies ARQ-151-301 or ARQ-151-302 | Arcutis Biotherapeutics, Inc. | $2,876 | 3 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | $1,198 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,330 | 6,305 | $506,635 | $171,106 |
| 2022 | 20 | 1,085 | 5,345 | $397,070 | $135,061 |
| 2021 | 14 | 765 | 1,588 | $289,904 | $94,945 |
| 2020 | 13 | 649 | 1,293 | $261,164 | $79,124 |
Total Patients
3,829
Total Services
14,531
Medicare Billing
$480,236
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 185 | 461 | $92,045 | $33,384 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 284 | $80,004 | $28,544 | 35.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 132 | 186 | $49,259 | $17,124 | 34.8% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 19 | 31 | $48,100 | $15,119 | 31.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 137 | 191 | $45,131 | $13,368 | 29.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 166 | 296 | $45,491 | $11,233 | 24.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 82 | 211 | $24,553 | $9,630 | 39.2% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 55 | 65 | $19,018 | $7,049 | 37.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 68 | 68 | $16,780 | $6,069 | 36.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 126 | 924 | $14,485 | $5,623 | 38.8% |
| 96574 | Application of light with debridement to destroy precancer skin growth | Office | 2023 | 14 | 16 | $10,659 | $4,178 | 39.2% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2023 | 14 | 3,200 | $10,592 | $4,155 | 39.2% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 20 | 33 | $13,480 | $3,975 | 29.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $7,289 | $2,840 | 39.0% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 15 | 29 | $9,880 | $2,478 | 25.1% |
| 96405 | Administration of chemotherapy into growth, 1-7 | Office | 2023 | 17 | 42 | $8,207 | $2,308 | 28.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 34 | 40 | $5,056 | $1,883 | 37.2% |
| 11105 | Punch biopsy, each additional skin growth | Office | 2023 | 12 | 20 | $2,736 | $1,073 | 39.2% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 18 | 25 | $3,260 | $844.23 | 25.9% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 18 | 103 | $480.00 | $182.20 | 38.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 18 | 60 | $132.59 | $49.58 | 37.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 156 | 393 | $79,386 | $27,989 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 114 | 202 | $57,457 | $20,498 | 35.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 108 | 152 | $40,371 | $13,529 | 33.5% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2022 | 17 | 22 | $33,969 | $10,589 | 31.2% |
About Dr. Shireen Guide, MD
Dr. Shireen Guide, MD is a Dermatology healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033287180.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shireen Guide, MD has received a total of $79,371 in payments from pharmaceutical and medical device companies, with $15,509 received in 2024. These payments were reported across 417 transactions from 45 companies. The most common payment nature is "" ($41,440).
As a Medicare-enrolled provider, Guide has provided services to 3,829 Medicare beneficiaries, totaling 14,531 services with total Medicare billing of $480,236. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties MOHS-Micrographic Surgery, Pediatric Dermatology
- Location Palo Alto, CA
- Active Since 11/30/2006
- Last Updated 04/29/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1033287180
Products in Payments
- VYJUVEK (Drug) $19,052
- Zoryve (Drug) $11,043
- VIJOICE (Drug) $2,728
- COSENTYX (Biological) $1,367
- DUPIXENT (Biological) $719.90
- EUCRISA (Drug) $718.08
- DORYX (Drug) $336.08
- RINVOQ (Biological) $330.21
- Otezla (Drug) $286.25
- TALTZ (Drug) $219.83
- COSENTYX (Drug) $218.94
- Hylatopic (Drug) $214.35
- Ceracade (Drug) $197.00
- Recell (Device) $175.00
- ADBRY (Biological) $150.41
- LIBTAYO (Biological) $149.74
- KERYDIN (Drug) $139.37
- OPZELURA (Drug) $130.08
- Humira (Biological) $126.68
- ORACEA (Drug) $122.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Palo Alto
John Doux, M.d, M.D
Dermatology — Payments: $124,944
Dermatology $124,944
Joyce Teng, Md, MD
Dermatology — Payments: $115,109
Dermatology $115,109
Ilka Netravali, Md, MD
Dermatology — Payments: $28,025
Dermatology $28,025
Dr. Daniel Navi, M.d, M.D
Dermatology — Payments: $19,065
Dermatology $19,065
Dr. Thomas Hoffman, M.d, M.D
Dermatology — Payments: $17,860
Dermatology $17,860
Dr. Miguel Canales, M.d, M.D
Dermatology — Payments: $8,023
Dermatology $8,023